Publicaciones en colaboración con investigadores/as de Stanford University School of Medicine (103)

2023

  1. Advanced MR Techniques for Preoperative Glioma Characterization: Part 1

    Journal of Magnetic Resonance Imaging, Vol. 57, Núm. 6, pp. 1655-1675

  2. Advanced MR Techniques for Preoperative Glioma Characterization: Part 2

    Journal of Magnetic Resonance Imaging, Vol. 57, Núm. 6, pp. 1676-1695

  3. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  4. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 2, pp. 328-343

  5. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  6. Development of a centralised triage centre for children with cancer and blood disorders in response to the humanitarian crisis in Ukraine

    The Lancet Oncology

  7. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  8. Food Insecurity and Chronic Kidney Disease: Considerations for Practitioners

    Journal of Renal Nutrition, Vol. 33, Núm. 5, pp. 691-697

  9. Identifying key multifunctional components shared by critical cancer and normal liver pathways via SparseGMM

    Cell Reports Methods, Vol. 3, Núm. 1

  10. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 6, pp. 1137-1154

  11. Long non-coding RNAs: definitions, functions, challenges and recommendations

    Nature Reviews Molecular Cell Biology, Vol. 24, Núm. 6, pp. 430-447

  12. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1